Seegene obtained CE IVDR marking for its Allplex MDRO Assay to detect multidrug-resistant organisms associated with healthcare-associated infections. The multiplex real-time PCR test identifies multiple key pathogens and resistance genes in a single assay, aiming to support faster first-line screening before culture-based confirmation is available. With the certification, Seegene launched the kit in Europe, expanding its infection control diagnostic portfolio for hospital settings. The company also signaled continued development of an Allplex MRSA Assay, targeting a 2027 European launch as part of a broader antimicrobial resistance pipeline. This marks another step for PCR-based stewardship tools that reduce time-to-interpretation in infection prevention and control pathways—an area increasingly important as hospitals manage escalating resistance threats.